Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0277 • ACR Convergence 2021
Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose A. Davila-Jimenez, Natalia Guajardo-Jauregui, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Alan De Leon-Yañez and Catalina Andrade-Vazquez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: A relationship between rheumatoid arthritis (RA) and the presence of abnormalities in left ventricular (LV) geometry such as eccentric remodeling has recently been determined,…
Abstract Number: 0295 • ACR Convergence 2021
Weight History and Associations with Cardiovascular Risk in Patients with Rheumatoid Arthritis
Lydia Federico¹, Kaleb Michaud², Kristin Wipfler³, Gulsen Ozen⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), but traditional CVD risk factors may not accurately characterize risk. For…
Abstract Number: 0514 • ACR Convergence 2021
Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹, Anil singh¹, Judy Vinh¹, H. Mark Kenney², Edward Schwarz³, David Fox⁴, Sadik Khuder⁵ and Salah-uddin Ahmed¹, ¹Washington State University, Spokane, WA, ²University of Rochester Medical Center, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Medicine and Public Health, University of Toledo,, Toledo, OH
Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
Abstract Number: 0577 • ACR Convergence 2021
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Diviya Rajesh, Deanna Jannat-Khah, Huong Do, Jonah Levine, Medha Barbhaiya, Lisa Mandl and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Higher comorbidity burden (CB) has been associated with treatment choices in RA, but not assessed in populations including multiple forms of inflammatory arthritis (IA)…
Abstract Number: 0607 • ACR Convergence 2021
Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review
Cheryl Barnabe¹, Aimee Wattiaux², Jennifer Petkovic³, Dorcas Beaton⁴, Beverley Shea³, Regina Greer-Smith⁵, Jennifer Humphreys⁶, Christie Bartels⁷, Peter Tugwell³ and Valerie Umaefulam¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Wisconsin, Madison, WI, ³University of Ottawa, Ottawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Healthcare Research Associates, Hazel Crest, IL, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Existing patient-reported outcome measures (PROMs) in rheumatoid arthritis (RA) may be limited in their applicability to populations that experience inequities. We conducted a systematic…
Abstract Number: 0762 • ACR Convergence 2021
Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform
Amy Boalch¹, Sam Norton¹, Sophia Steer², Nicky Wilson² and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: The Musculoskeletal Health Questionnaire (MSK-HQ) is a patient reported outcome measure (PROM) validated to assess disease outcomes in patients with MSK disorders. This study…
Abstract Number: 0802 • ACR Convergence 2021
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Laval University, Québec City, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Providence Health Care, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montreal, ON, Canada
Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
Abstract Number: 0820 • ACR Convergence 2021
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1066 • ACR Convergence 2021
Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
Pedro Santos-Moreno¹, Rosangela Casanova², Gabriel-Santiago Rodríguez-Vargas², Laura Villareal¹, Jaime-Andrés Rubio², Josefina Chávez-Chávez², Diana Patricia Rivera-Triana², Ruth Alexandra Castiblanco-Montañez², Sandra Milena Hernández-Zambrano² and Adriana Rojas-Villarraga², ¹BIOMAB IPS, Bogotá, Colombia, ²Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
Background/Purpose: The COVID-19 pandemic impacted everyday practice pattern of health care in rheumatoid arthritis (RA) patients. The objective was to evaluate the implementation of a…
Abstract Number: 1197 • ACR Convergence 2021
Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
Adelina Plachokova¹, Jill Hadisurya¹, Julia van Bergen² and Rogier Thurlings³, ¹Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, Netherlands, ²Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, ³Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Transversal cohort studies demonstrated a possible association between periodontal disease (PD) and rheumatoid arthritis (RA). However it is unknown how this association evolves during…
Abstract Number: 1213 • ACR Convergence 2021
Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge
Christoph Baerwald¹, Edgar Stemmler², Sixten Gnuechtel², Katharina Birkner², Carsten Holland³, Bjoern Fritz², Daniela Adolf⁴ and Ralf Baron⁵, ¹University Hospital Leipzig, Leipzig, Germany, ²AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, ³AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁴StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁵University Hospital Schleswig-Holstein, Kiel, Germany
Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
Abstract Number: 1229 • ACR Convergence 2021
Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Rieke Alten¹, Xavier Mariette², Melanie Chartier³, Christiane Rauch⁴, Yedid Elbez⁵, Karissa Lozenski⁶ and Vadim Khaychuk⁶, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Bristol Myers Squibb, Rueil-Malmaison, France, ⁴Bristol Myers Squibb, Munich, Germany, ⁵Deepscover, Puteaux, France, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: BMI has been shown to affect treatment response and may influence the development of optimal individualized treatment plans in patients with RA.1 The extent…
Abstract Number: 1245 • ACR Convergence 2021
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
Cecile PHILIPPOTEAUX¹, Valentine DEPREZ², Jean-Guillaume LETAROUILLY¹, Emeline CAILLIAU³, Eric HOUVENAGEL⁴, Xavier DEPREZ⁵, Aurore NOTTEZ⁶, Peggy PHILIPPE¹, Tristan PASCART⁷, Vincent GOEB² and Rene-Marc FLIPO⁸, ¹Rheumatology Department, University Hospital of Lille, Lille, France, ²Rheumatology Department, University Hospital of Amiens, Amiens, France, ³Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, ⁴Rheumatology Department, Lille Catholic Hospitals, Lomme, France, ⁵Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, ⁶Rheumatology Department, University Hospital of Dunkerque, Dunkerque, France, ⁷Department of Rheumatology, Lille Catholic Hospitals, Lomme, France, ⁸Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: In recent decades, the therapeutic arsenal in RA has dramatically expanded. Baricitinib (BARI) and Tofacitinib (TOFA) were the first JAK inhibitors (JAKi) to be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].